Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road AheadJimmy El Hokayem1, Holly N Cukier1,2# and Derek M Dykxhoorn1,3*
- *Corresponding Author:
- Derek M. Dykxhoorn
John P. Hussman Institute for Human Genomics
University of Miami Miller School of Medicine
1501 NW 10th Ave, Biomedical Research Building
Room 509, Miami, USA
Tel: (305) 243-7596
E-mail: [email protected]
Received date October 13, 2016; Accepted date October 18, 2016; Published date October 25, 2016
Citation: Hokayem JEl, Cukier HN, Dykxhoorn DM (2016) Blood Derived Induced Pluripotent Stem Cells (iPSCs): Benefits, Challenges and the Road Ahead. J Alzheimers Dis Parkinsonism 6:275. doi: 10.4172/2161-0460.1000275
Copyright: © 2016 Hokayem JEl, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Since the creation of induced Pluripotent Stem Cells (iPSCs) ten years ago, hundreds of publications have demonstrated their considerable impact on disease modeling and therapy. In this commentary, we will summarize key milestones, benefits and challenges in the iPSC field. Furthermore, we will highlight blood as an effective and easily accessible source for patient-specific iPSCs derivation in the context of work done in our laboratory and others.